|
[1]ALETAHA D,NEOGI T,SILMAN AJ,et al.2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative[J].Arthritis Rheum,2010,62(9):2569.
|
|
[2]JOHNSON PJ,Mc FARLANE IG.Meeting report:International autoimmune hepatitis group[J].Hepatology,1993,18:998-1005.
|
|
[3]Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association;Chinese Society of Infectious Diseases,Chinese Medical Association.Consensus on the diagnosis and management of autoimmune hepatitis(2015)[J].J Clin Hepatol,2016,32(1):9-22.(in Chinese)中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.自身免疫性肝炎诊断和治疗共识(2015)[J].临床肝胆病杂志,2016,32(1):9-22.
|
|
[4]SMOLEN JS,LANDEWR,BREEDVELD FC,et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2013 update[J].Ann Rheum Dis,2014,73(3):492-509.
|
|
[5]ZENG XF,ZHU SL,TAN AC,et al.Disease burden and quality of life of rheumatoid arthritis in China:a systematic review[J].Chin J Evid-based Med,2013,13(3):300-307.(in Chinese)曾小峰,朱松林,谭爱春,等.我国类风湿关节炎疾病负担和生存质量研究的系统评价[J].中国循证医学杂志,2013,13(3):300-307.
|
|
[6]WANG S.Clinical observation on effect of biological agent etanercept cmbined with methotrexate in treatment of refractory rheumatoid arthritis[J].Chongqing Med,2013,42(26):3100-3101,3104.(in Chinese)汪珊.生物制剂益赛普联合甲氨蝶呤治疗难治性类风湿关节炎的疗效观察[J].重庆医学,2013,42(26):3100-3101,3104.
|
|
[7]CHENG JW,LI XF,ZHANG LY,et al.The clinical efficacy and safety of short-term combination therapy with etanercept,methotrexate and cyclophosphamide for rheumatoid arthritis[J].Chin J Rheumatol,2008,12(7):480-483.(in Chinese)陈俊伟,李小峰,张莉芸,等.短期益赛普与甲氨蝶呤环磷酰胺联合治疗类风湿关节炎的临床研究[J].中华风湿病学杂志,2008,12(7):480-483.
|
|
[8]CHERAVSKY AC,PALADINO N,RUBIO AE,et al.Simultaneous expression of Th1 cytokines and IL-4 confers severe characteristics to type I autoimmune hepatitis in children[J].Hum Immunol,2004,65(7):683-691.
|
|
[9]CALABRESE LH.Molecular differences in anticytokine therapies[J].Clin Exp Rheumatol,2003,21(2):241-248.
|
|
[10]KLINKHOFF A.Biological agents for rheumatoid arthritis:targeting both physical function and structural damage[J].Drugs,2004,64(12):1267-1283.
|
|
[11]SPADARO A,SCRIVO R,RICCIERI V,et al.Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis[J].Joint Bone Spine,2008,75(1):87-89.
|
|
[12]SOKKA T,HETLAND ML,MKINEN H,et al.Remission and rheumatoid arthritis:data on patients receiving usual care in twenty-four countries[J].Arthritis Rheum,2008,58(9):2642-2651.
|
|
[13]LUTF A,POIL AR,HAMMOUDEH M.Characteristics of patients with rheumatoid arthritis in Qatar:a cross-sectional study[J].Int J Rheum Dis,2014,17(1):63-65.
|
|
[14]WANG GY,ZHANG SL,WANG XR,et al.Remission of rheumatoid arthritis and potential determinants:a national multi-center crosssectional survey[J].Clin Rheumatol,2015,34(2):221-230.
|
|
[15]EFE C.Drug induced autoimmune hepatitis and TNF-αblocking agents:is there a real relationship?[J].Autoimmun Rev,2013,12(3):337-339.
|
|
[16]OZORIO G,Mc GARITY B,BAK H,et al.Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis[J].Med J Aust,2007,187(9):524-526.
|
|
[17]HARADA K,AKAI Y,KOYAMA S,et al.A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis[J].Clin Rheumatol,2008,27(8):1063-1066.
|
DownLoad: